{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T05:20:12Z","timestamp":1792819212194,"version":"4.5.0"},"reference-count":38,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction:<\/jats:title>\n                    <jats:p>\n                      To prospectively compare the diagnostic value of\n                      <jats:sup>18<\/jats:sup>\n                      F-meta-fluorobenzylguanidine ([\n                      <jats:sup>18<\/jats:sup>\n                      F]MFBG) and [\n                      <jats:sup>68<\/jats:sup>\n                      Ga]Ga-DOTA-TATE PET\/CT in pediatric patients with suspected recurrent\/refractory neuroblastoma.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Between December 2024 and March 2025, 28 children (18 boys, 10 girls; mean age \u00b1 SD 4.8 \u00b1 2.5\u00a0y) underwent both tracers within 1 week at a single institution. Physiological biodistribution, image quality, lesion conspicuity, semiquantitative uptake (SUVmax), Curie score, and response classification were analyzed side-by-side.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      [\n                      <jats:sup>18<\/jats:sup>\n                      F]MFBG showed higher background than [\n                      <jats:sup>68<\/jats:sup>\n                      Ga]Ga-DOTA-TATE in skeletal muscle but lower activity in articular metaphyses, pituitary, and kidneys. Heterogeneous distribution of [\n                      <jats:sup>18<\/jats:sup>\n                      F]MFBG was more common in the liver, while notable uptake differences were observed in the pancreas with [\n                      <jats:sup>68<\/jats:sup>\n                      Ga]Ga-DOTA-TATE. Patient-level concordance was high (both scans positive in 15, negative in 7); discordance occurred in 6 patients (2 MFBG+\/DOTA-TATE-, 4 MFBG-\/DOTA-TATE+). Region-level analysis encompassed 86 relapsed or metastatic regions in 17 patients. [\n                      <jats:sup>18<\/jats:sup>\n                      F]MFBG detected 80 regions (sensitivity 93.0%, specificity 96.4%, AUC 0.947), whereas [\n                      <jats:sup>68<\/jats:sup>\n                      Ga]Ga-DOTA-TATE detected 82 (sensitivity 95.4%, specificity 86.6%, AUC 0.910). Superior specificity of [\n                      <jats:sup>18<\/jats:sup>\n                      F]MFBG stemmed largely from its higher uptake in bone\/marrow metastases compared with [\n                      <jats:sup>68<\/jats:sup>\n                      Ga]Ga-DOTA-TATE (median SUVmax 5.21 vs. 2.90,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt;0.0001). Region-level concordance revealed 78 concordant positive sites and 39 discordant sites (9 MFBG+\/DOTA-TATE-, 30 MFBG-\/DOTA-TATE+). Aggregate Curie scores were identical (155 each). Because uptake patterns were complementary, combining both tracers improved visual confidence in heterogeneous tumors and refined treatment-response categorization.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>\n                      [\n                      <jats:sup>18<\/jats:sup>\n                      F]MFBG and [\n                      <jats:sup>68<\/jats:sup>\n                      Ga]Ga-DOTA-TATE PET\/CT imaging are effective for evaluating relapsed or metastatic neuroblastoma because they show lower uptake in normal organs and benign lesions. The 2 imaging modalities offer complementary value in tumor detection and assessment of treatment response due to tumor spatial heterogeneity.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/rlu.0000000000006308","type":"journal-article","created":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T15:01:21Z","timestamp":1770044481000},"page":"385-397","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":4,"title":["Head-to-Head Comparison of [18F]MFBG and [68Ga]Ga-DOTA-TATE PET\/CT in Suspected Recurrent\/Refractory Neuroblastoma: Prospective Single-center Analysis"],"prefix":"10.1097","volume":"51","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2873-3172","authenticated-orcid":false,"given":"Qinfeng","family":"Xu","sequence":"first","affiliation":[{"name":"Department of Nuclear Medicine, Jiangsu Province Hospital of Chinese Medicine, The Affiliated Hospital of Nanjing University of Chinese Medicine"},{"name":"Department of Nuclear Medicine, Nanjing First Hospital, Nanjing Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3627-0902","authenticated-orcid":false,"given":"Yueran","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Nanjing First Hospital, Nanjing Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-9036-8275","authenticated-orcid":false,"given":"Jieping","family":"Song","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Nanjing First Hospital, Nanjing Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1448-2982","authenticated-orcid":false,"given":"Wanhua","family":"Guo","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Nanjing Tongren Hospital, School of Medicine, Southeast University, Nanjing, Jiangsu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoqiang","family":"Shao","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Nanjing First Hospital, Nanjing Medical University"},{"name":"The Engineering Research Center of Synthetic Peptide Drug Discovery and Evaluation of Jiangsu Province, China Pharmaceutical University, Nanjing, Jiangsu"},{"name":"Department of Nuclear Medicine, Ma'anshan People\u2019s Hospital, Ma'anshan, Anhui"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,1,20]]},"reference":[{"key":"R1-20260401","doi-asserted-by":"crossref","first-page":"j1863","DOI":"10.1136\/bmj.j1863","article-title":"Neuroblastoma","volume":"357","author":"Shohet","year":"2017","journal-title":"Brit Med J"},{"key":"R2-20260401","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s10555-020-09946-y","article-title":"Neuroblastoma and the epigenome","volume":"40","author":"Fetahu","year":"2021","journal-title":"Cancer Metastasis Rev"},{"key":"R3-20260401","doi-asserted-by":"crossref","first-page":"3229","DOI":"10.1200\/JCO.21.00278","article-title":"Revised neuroblastoma risk classification system: a report from the Children\u2019s Oncology group","volume":"39","author":"Irwin","year":"2021","journal-title":"J Clin Oncol"},{"key":"R4-20260401","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1002\/med.21750","article-title":"Molecular targeting therapies for neuroblastoma: Progress and challenges","volume":"41","author":"Zafar","year":"2021","journal-title":"Med Res Rev"},{"key":"R5-20260401","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1148\/radiol.11101352","article-title":"Guidelines for imaging and staging of neuroblastic tumors: consensus report from the International Neuroblastoma Risk Group Project","volume":"261","author":"Brisse","year":"2011","journal-title":"Radiology"},{"key":"R6-20260401","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1007\/s00259-018-4070-8","article-title":"Guidelines on nuclear medicine imaging in neuroblastoma","volume":"45","author":"Bar-Sever","year":"2018","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R7-20260401","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1007\/s00259-011-1843-8","article-title":"123I-MIBG scintigraphy\/SPECT versus 18F-FDG PET in paediatric neuroblastoma","volume":"38","author":"Melzer","year":"2011","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R8-20260401","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1038\/sj.bjc.6605621","article-title":"Criteria for evaluation of disease extent by 123I-metaiodobenzylguanidine scans in neuroblastoma: a report for the International Neuroblastoma Risk Group (INRG) Task Force","volume":"102","author":"Matthay","year":"2010","journal-title":"Br J Cancer"},{"key":"R9-20260401","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1200\/JCO.2012.45.8794","article-title":"Iodine-123 metaiodobenzylguanidine scintigraphy scoring allows prediction of outcome in patients with stage 4 neuroblastoma: results of the Cologne interscore comparison study","volume":"31","author":"Decarolis","year":"2013","journal-title":"J Clin Oncol"},{"key":"R10-20260401","doi-asserted-by":"crossref","first-page":"3097","DOI":"10.1007\/s00259-023-06221-4","article-title":"[(18)F]MFBG PET\/CT outperforming [(123)I]MIBG SPECT\/CT in the evaluation of neuroblastoma","volume":"50","author":"Wang","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R11-20260401","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1007\/s00259-022-06046-7","article-title":"[18F] MFBG PET imaging: biodistribution, pharmacokinetics, and comparison with [123I] MIBG in neural crest tumour patients","volume":"50","author":"Pauwels","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R12-20260401","doi-asserted-by":"crossref","first-page":"4459","DOI":"10.21873\/anticanres.10990","article-title":"68Ga-DOTATOC and FDG PET imaging of preclinical neuroblastoma models","volume":"36","author":"Provost","year":"2016","journal-title":"Anticancer Res"},{"key":"R13-20260401","doi-asserted-by":"crossref","first-page":"270","DOI":"10.3390\/jpm11040270","article-title":"Nuclear medicine imaging in neuroblastoma: current status and new developments","volume":"11","author":"Samim","year":"2021","journal-title":"J Pers Med"},{"key":"R14-20260401","doi-asserted-by":"crossref","first-page":"39S","DOI":"10.2967\/jnumed.116.186833","article-title":"Norepinephrine transporter as a target for imaging and therapy","volume":"58","author":"Pandit-Taskar","year":"2017","journal-title":"J Nucl Med"},{"key":"R15-20260401","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1097\/RLU.0000000000003577","article-title":"Feasibility and therapeutic potential of combined Peptide Receptor Radionuclide Therapy with intensive chemotherapy for pediatric patients with relapsed or refractory metastatic neuroblastoma","volume":"46","author":"Fathpour","year":"2021","journal-title":"Clin Nucl Med"},{"key":"R16-20260401","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1097\/RLU.0000000000002961","article-title":"The complementary role of 68Ga-DOTATATE PET\/CT in neuroblastoma","volume":"45","author":"Telli","year":"2020","journal-title":"Clin Nucl Med"},{"key":"R17-20260401","doi-asserted-by":"crossref","first-page":"e339","DOI":"10.1097\/RLU.0000000000003495","article-title":"Meningeal relapse of neuroblastoma-utility of 68Ga-DOTATOC PET\/CT for detection","volume":"46","author":"Kashyap","year":"2021","journal-title":"Clin Nucl Med"},{"key":"R18-20260401","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1097\/MPH.0000000000000411","article-title":"Initial experience with Gallium-68 DOTA-Octreotate PET\/CT and Peptide Receptor Radionuclide Therapy for pediatric patients with refractory metastatic neuroblastoma","volume":"38","author":"Kong","year":"2016","journal-title":"J Pediatr Hematol Oncol"},{"key":"R19-20260401","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1097\/MNM.0000000000001096","article-title":"Prospective evaluation of 68Ga-DOTANOC positron emission tomography\/computed tomography and 131I-meta-iodobenzylguanidine single-photon emission computed tomography\/computed tomography in extra-adrenal paragangliomas, including uncommon primary sites and to define their diagnostic roles in current scenario","volume":"40","author":"Arora","year":"2019","journal-title":"Nucl Med Commun"},{"key":"R20-20260401","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1007\/s11864-019-0678-6","article-title":"Molecular imaging and therapy for neuroendocrine tumors","volume":"20","author":"Desai","year":"2019","journal-title":"Curr Treat Options Oncol"},{"key":"R21-20260401","doi-asserted-by":"crossref","first-page":"815","DOI":"10.2967\/jnumed.117.201525","article-title":"Radiolabeled (4-Fluoro-3-Iodobenzyl)Guanidine improves imaging and targeted radionuclide therapy of norepinephrine transporter-expressing tumors","volume":"59","author":"Yamaguchi","year":"2018","journal-title":"J Nucl Med"},{"key":"R22-20260401","doi-asserted-by":"crossref","first-page":"147","DOI":"10.2967\/jnumed.117.193169","article-title":"Biodistribution and Dosimetry of (18)F-Meta-Fluorobenzylguanidine: a first-in-human PET\/CT imaging study of patients with neuroendocrine malignancies","volume":"59","author":"Pandit-Taskar","year":"2018","journal-title":"J Nucl Med"},{"key":"R23-20260401","doi-asserted-by":"crossref","first-page":"20918","DOI":"10.1038\/s41598-020-77788-3","article-title":"(18)F-meta-fluorobenzylguanidine ((18)F-mFBG) to monitor changes in norepinephrine transporter expression in response to therapeutic intervention in neuroblastoma models","volume":"10","author":"Turnock","year":"2020","journal-title":"Sci Rep"},{"key":"R24-20260401","doi-asserted-by":"crossref","first-page":"541","DOI":"10.2967\/jnumed.112.112334","article-title":"Semiquantitative mIBG scoring as a prognostic indicator in patients with stage 4 neuroblastoma: a report from the Children\u2019s oncology group","volume":"54","author":"Yanik","year":"2013","journal-title":"J Nucl Med"},{"key":"R25-20260401","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1097\/RLU.0b013e31825b2555","article-title":"Semiquantitative analysis and characterization of physiological biodistribution of 68Ga-DOTA-TATE PET\/CT","volume":"37","author":"Kunikowska","year":"2012","journal-title":"Clin Nucl Med"},{"key":"R26-20260401","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1097\/RLU.0000000000002539","article-title":"68Ga-DOTA-TATE in neuroblastoma with marrow involvement","volume":"44","author":"Torun","year":"2019","journal-title":"Clin Nucl Med"},{"key":"R27-20260401","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1007\/s12105-021-01329-1","article-title":"SSTR2 expression in olfactory neuroblastoma: clinical and therapeutic implications","volume":"15","author":"Cracolici","year":"2021","journal-title":"Head Neck Pathol"},{"key":"R28-20260401","doi-asserted-by":"crossref","first-page":"490","DOI":"10.2967\/jnumed.124.269121","article-title":"Theranostics for neuroblastoma: making molecular radiotherapy work better","volume":"66","author":"Gawne","year":"2025","journal-title":"J Nucl Med"},{"key":"R29-20260401","doi-asserted-by":"crossref","first-page":"2182","DOI":"10.1158\/1078-0432.CCR-13-1153","article-title":"Imaging the norepinephrine transporter in neuroblastoma: a comparison of [18F]-MFBG and 123I-MIBG","volume":"20","author":"Zhang","year":"2014","journal-title":"Clin Cancer Res"},{"key":"R30-20260401","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1097\/MNM.0000000000001265","article-title":"68Ga-DOTATATE and 123I-mIBG as imaging biomarkers of disease localisation in metastatic neuroblastoma: implications for molecular radiotherapy","volume":"41","author":"Gains","year":"2020","journal-title":"Nucl Med Commun"},{"key":"R31-20260401","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1053\/j.semnuclmed.2016.10.007","article-title":"Neuroblastoma: MIBG imaging and new tracers","volume":"47","author":"Pfluger","year":"2017","journal-title":"Semin Nucl Med"},{"key":"R32-20260401","doi-asserted-by":"crossref","first-page":"150859","DOI":"10.1016\/j.sempedsurg.2019.150859","article-title":"MIBG in neuroblastoma diagnosis and treatment","volume":"28","author":"Olecki","year":"2019","journal-title":"Semin Pediatr Surg"},{"key":"R33-20260401","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1093\/jnen\/nlad068","article-title":"Maturation of metastases in peripheral neuroblastic tumors (neuroblastoma) of children","volume":"82","author":"Sarnat","year":"2023","journal-title":"J Neuropathol Exp Neurol"},{"key":"R34-20260401","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1267\/ahc.14024","article-title":"Expressions of Somatostatin Receptor Subtypes (SSTR-1, 2, 3, 4 and 5) in neuroblastic tumors; special reference to clinicopathological correlations with international neuroblastoma pathology classification and outcomes","volume":"47","author":"Watanabe","year":"2014","journal-title":"Acta Histochem Cytochem"},{"key":"R35-20260401","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.clon.2021.03.003","article-title":"The association between tumour markers and meta-iodobenzylguanidine scans in south african children with high-risk neuroblastoma","volume":"33","author":"Van Heerden","year":"2021","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"R36-20260401","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1097\/MPH.0000000000001326","article-title":"Prevalence and clinical correlations of Somatostatin Receptor-2 (SSTR2) expression in neuroblastoma","volume":"41","author":"Alexander","year":"2019","journal-title":"J Pediatr Hematol Oncol"},{"key":"R37-20260401","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.1016\/S0959-8049(97)00212-8","article-title":"Somatostatin in neuroblastoma and ganglioneuroma","volume":"33","author":"Kogner","year":"1997","journal-title":"Eur J Cancer"},{"key":"R38-20260401","article-title":"[18F]MFBG PET\/CT is an effective and preferable imaging modality for neuroblastoma in a prospective comparison with SSTR PET","author":"Wang","year":"2025","journal-title":"Eur J Nucl Med Mol Imaging"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000006308","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T21:00:44Z","timestamp":1775077244000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000006308"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,20]]},"references-count":38,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0000000000006308","relation":{},"ISSN":["0363-9762","1536-0229"],"issn-type":[{"value":"0363-9762","type":"print"},{"value":"1536-0229","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,20]]},"assertion":[{"value":"2025-09-05","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-12-19","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}